Now showing items 1-2 of 2

    • Carboplatin in BRCA1/2-mutated and triple-negative breast cancer BRCAness subgroups: the TNT Trial. 

      Tutt, A; Tovey, H; Cheang, MCU; Kernaghan, S; Kilburn, L; et al. (NATURE PUBLISHING GROUP, 2018-04-30)
      Germline mutations in BRCA1/2 predispose individuals to breast cancer (termed germline-mutated BRCA1/2 breast cancer, gBRCA-BC) by impairing homologous recombination (HR) and causing genomic instability. HR also repairs ...
    • Pan-cancer analysis of whole genomes. 

      ICGC/TCGA Pan-Cancer Analysis of Whole Genomes Consortium, (NATURE PORTFOLIO, 2020-02-06)
      Cancer is driven by genetic change, and the advent of massively parallel sequencing has enabled systematic documentation of this variation at the whole-genome scale1-3. Here we report the integrative analysis of ...